Stem Cell Transplantation and Cellular Therapy

Expert Stem Cell Transplantation and Cellular Therapy Program

The Stem Cell Transplantation and Cellular Therapy Program is one of the largest and most established in Illinois. Since our first transplant in 1986, our physicians have performed more than three thousand transplants.

Loyola Medicine has been recognized as a National Marrow Donor Program (NMDP)/Be The Match transplant and collection center since December 1996. As a designated center of excellence, Loyola’s program has held FACT accreditation since 2002; this prestigious accreditation ensures the highest standards of patient care.

Our interdisciplinary team of doctors is dedicated to research and improvement of the transplant process. The program offers a comprehensive range of treatments, such as autologous and allogeneic stem cell transplants and the recent addition of Chimeric Antigen Receptor T-cell (CAR-T) therapies, as well as a variety of clinical trials. We offer all standard of care cellular therapies across all diseases indications, including:

Blood and Bone Marrow Transplant Clinical Trials

We are proud to offer both newly diagnosed and relapsed patients the opportunities to participate in clinical trials to potentially improve upon current outcomes and expectations. We are the only core member of the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) in Illinois, giving patients unique opportunities in the Chicagoland area. It is through these efforts that we have been able to consistently improve patient outcomes and survival rates.

Clinical Trial Saves Leukemia Patient


What is Cellular Therapy?

Cellular therapy refers to a variety of different treatments that harness the immune system to fight cancer. Originally, this was referred to as a "bone marrow transplant" or a "stem cell transplant" but has now expanded to also include CAR-T therapy.

Bone marrow is found in the center cavities of all bones and within the ends of the long bones of your arms and legs. It is composed of stem cells that give origin to:

  • Red cells (RBC) or erythrocytes that are responsible for carrying oxygen to all body tissues and organ
  • White cells (WBC) or leukocytes that kill germs that can cause infection
  • Platelets which are responsible for clotting and preventing excessive bleeding

Stem cells multiply, divide and mature in the bone marrow. They are released into the bloodstream as red blood cells, white blood cells and platelets.

Types of Cellular Therapy

Cellular therapy is most commonly used to treat lymphoma, leukemia, and multiple myeloma. However, this treatment option can also be used to treat other cancers such as neuroblastoma, ovarian cancer, testicular cancer, and rarely auto-immune diseases.

Your specific diagnosis will determine the type of cellular therapy that may benefit you. There are three types of cellular therapy:

Allogeneic transplant is a transplant of stem cells from one person to another. The donor may be a blood relative (such as a sibling, child, or rarely parent) or someone unrelated (such as a volunteer donor from around the world; or umbilical cord blood). A donor match is determined by a laboratory test called HLA typing. The goal is to replace unhealthy stem cells with healthy stem cells that can then "fight" the cancer and eliminate it for good.

Autologous transplant is a transplant where the patient acts as his or her own donor ("auto"). Peripheral blood stem cells (taken from a blood vessel) are removed, stored and given back to the patient at a later date. This allows treatments with higher, more effective doses of chemotherapy to be given safely and increases long-term remission rates and overall survival. The goal of receiving the “auto” stem cells is to replace bone marrow cells that are damaged while treating cancer with high-dose therapy. The new cells from a transplant will cause the bone marrow to function normally again.

CAR-T therapy is a treatment where a patients lymphocytes are collected. The T-cells (a type of lymphocyte) are then selected and programed to fight the cancer by placing a novel receptor ("CAR") into them that can recognize the cancer (multiple myeloma, acute lymphoblastic leukemia, non-hodgkins lymphoma, and more recently chronic lymphocytic leukemia). The goal is for those modified immune cells to recognize cancer cells and active your immune system to get rid of them.

Patient Stories

Clinical Trial Saves Leukemia Patient

Loyola Patient Overcomes Amyloidosis, a Rare Blood Cancer

Featured Videos

Allogeneic Stem Cell Transplantation for Blood or Bone Marrow Cancers

Advanced Treatment Options for Multiple Myeloma

Featured Blogs